ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1535

Phenotype Of Patients and Impact Of The Disease In Early Spondyloarthritis Are Similar Regardless The Arm Of The Assessment In Spondyloarthritis International Society Criteria (“imaging” or “clinical”) Fulfilled By The Patients. Data From The DESIR Cohort

Anna Molto1, Simon Paternotte2, Désirée van der Heijde3, Pascal Claudepierre4, Martin Rudwaleit5 and Maxime Dougados1, 1Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, 2Rheumatology Department, Paris- Descartes University, Cochin hospital, Paris, France, 3Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4Rheumatology, Henri Mondor Teaching Hospital, AP-HP, Créteil, France, 5Endokrinologikum Berlin, Berlin, Germany

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Clinical and spondylarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Patients can fulfil the ASAS (Assessment of SpondyloArthritiS) sets of criteria with either objective evidence of sacroiliac joint damage (X-Ray) or inflammation (MRI): (“imaging” arm) or without such imaging abnormalities in B27 patients (“clinical” arm). The clinical arm is not well recognized by the medical community and the health care systems.The aim of this study was to compare the phenotype but also the impact of the disease on the daily life of the patients with regard to the 2 different arms (e.g. “imaging” versus “clinical”) of early spondyloarthritis patients.

Methods:  Study design:  prospective, multi-centre, observational study. Patients: 708 patients with early inflammatory back pain suggestive of spondyloarthritis have been included in the DESIR cohort. Data collected: demographics, items of the ASAS criteria, disease activity, severity. Statistical analysis: The patients fulfilling the ASAS criteria were split in two groups regarding the presence of imaging (X-ray or MRI) abnormalities of the sacroiliac joints (e.g. imaging arm), and within the clinical arm, with regard to the presence of CRP abnormality (e.g. >6mg/L). 

Results:

Of the 708 recruited patients, lack of missing data permitted to classify 682 patients according to the ASAS criteria: 206 (30.2%) did not fulfill them; of the 476 (69.8%) remaining patients, 296 (60.1%) and 190 (39.9%) fulfilled the imaging and clinical arm respectively. Comparison in the patients (age, gender, B27 positivity) and disease (clinical presentation, activity and severity) characteristics fulfilling the two arms of the ASAS criteria for axial SpA showed no differences between both groups except in terms of age, gender and CRP: younger patients, more males and higher CRP values in the “imaging” arm. The multiple logistic regression analysis (by including all variables with a p<0.20 in univariated analyses) confirmed the positive association of male gender (OR 1.70 [1.12 – 2.58]) and ASDAS-CRP (OR 2.44 [1.73 – 3.44]) with the “imaging” arm.

Conclusion: This study suggests that despite some differences (e.g. gender, inflammation) the impact of the disease on daily activities were similar in both arms (e.g. imaging vs. clinical) and therefore therapeutical strategies and access to care in disabled patients should be identical regardless the arm of the ASAS criteria they are fulfilling.


Disclosure:

A. Molto,
None;

S. Paternotte,
None;

D. van der Heijde,

AbbVie, Amgen, AstraZeneca, Augurex, BMS, Celgene, Chugai, Covagen, Daiichi, Eli-Lilly, GSK, Janssen Biologics, Merck, Novartis, Novo-Nordisk, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB, Vertex,

9,

Imaging Rheumatology,BV,

9;

P. Claudepierre,
None;

M. Rudwaleit,
None;

M. Dougados,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/phenotype-of-patients-and-impact-of-the-disease-in-early-spondyloarthritis-are-similar-regardless-the-arm-of-the-assessment-in-spondyloarthritis-international-society-criteria-imaging/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology